1. Home
  2. CINGW vs CNXN Comparison

CINGW vs CNXN Comparison

Compare CINGW & CNXN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CINGW
  • CNXN
  • Stock Information
  • Founded
  • CINGW N/A
  • CNXN 1982
  • Country
  • CINGW United States
  • CNXN United States
  • Employees
  • CINGW 13
  • CNXN N/A
  • Industry
  • CINGW Biotechnology: Pharmaceutical Preparations
  • CNXN Catalog/Specialty Distribution
  • Sector
  • CINGW Health Care
  • CNXN Consumer Discretionary
  • Exchange
  • CINGW Nasdaq
  • CNXN Nasdaq
  • Market Cap
  • CINGW N/A
  • CNXN N/A
  • IPO Year
  • CINGW 2021
  • CNXN 1998
  • Fundamental
  • Price
  • CINGW $0.07
  • CNXN $74.04
  • Analyst Decision
  • CINGW
  • CNXN
  • Analyst Count
  • CINGW 0
  • CNXN 0
  • Target Price
  • CINGW N/A
  • CNXN N/A
  • AVG Volume (30 Days)
  • CINGW N/A
  • CNXN 116.9K
  • Earning Date
  • CINGW N/A
  • CNXN 10-30-2024
  • Dividend Yield
  • CINGW N/A
  • CNXN 0.54%
  • EPS Growth
  • CINGW N/A
  • CNXN 17.07
  • EPS
  • CINGW N/A
  • CNXN 3.35
  • Revenue
  • CINGW N/A
  • CNXN $2,758,056,000.00
  • Revenue This Year
  • CINGW N/A
  • CNXN $2.01
  • Revenue Next Year
  • CINGW N/A
  • CNXN $7.29
  • P/E Ratio
  • CINGW N/A
  • CNXN $22.03
  • Revenue Growth
  • CINGW N/A
  • CNXN N/A
  • 52 Week Low
  • CINGW N/A
  • CNXN $51.64
  • 52 Week High
  • CINGW N/A
  • CNXN $77.19
  • Technical
  • Relative Strength Index (RSI)
  • CINGW N/A
  • CNXN 54.35
  • Support Level
  • CINGW N/A
  • CNXN $72.55
  • Resistance Level
  • CINGW N/A
  • CNXN $73.73
  • Average True Range (ATR)
  • CINGW 0.00
  • CNXN 1.56
  • MACD
  • CINGW 0.00
  • CNXN -0.27
  • Stochastic Oscillator
  • CINGW 0.00
  • CNXN 34.92

About CINGW Cingulate Inc.

Cingulate Inc is a clinical-stage biopharmaceutical company utilizing its proprietary precision timed-release drug delivery platform to build and advance a pipeline of next-generation pharmaceutical products designed to improve the lives of patients suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes. The company focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety, and identifying and evaluating additional therapeutic areas to use PTR technology to develop future product candidates.

Share on Social Networks: